MYC and hepatocellular carcinoma: We have shown that treatment with the non-cytotoxic glucose-starvation mimetic aldometanib can reduce tumor sizes in HCC spontaneously developed in DEN-HFD and MYC;Trp53−/− mice and in orthotopic allografts of various origins, including Hepa1-6 and patient-derived HCC cells.